letrox 100mcg tableta
berlin-chemie ag, berlín array - 828 sodnÁ sŮl levothyroxinu - tableta - 100mcg - sodnÁ sŮl levothyroxinu
letrox 125mcg tableta
berlin-chemie ag, berlín array - 828 sodnÁ sŮl levothyroxinu - tableta - 125mcg - sodnÁ sŮl levothyroxinu
letrox 150mcg tableta
berlin-chemie ag, berlín array - 828 sodnÁ sŮl levothyroxinu - tableta - 150mcg - sodnÁ sŮl levothyroxinu
letrox 25mcg tableta
berlin-chemie ag, berlín array - 828 sodnÁ sŮl levothyroxinu - tableta - 25mcg - sodnÁ sŮl levothyroxinu
letrox 50mcg tableta
berlin-chemie ag, berlín array - 828 sodnÁ sŮl levothyroxinu - tableta - 50mcg - sodnÁ sŮl levothyroxinu
letrox 75mcg tableta
berlin-chemie ag, berlín array - 828 sodnÁ sŮl levothyroxinu - tableta - 75mcg - sodnÁ sŮl levothyroxinu
kaftrio
vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cystická fibróza - jiné produkty dýchacích cest - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
symkevi
vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cystická fibróza - jiné produkty dýchacích cest - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.
anvildis 50mg tableta
vipharm s.a., ożarów mazowiecki array - 17128 vildagliptin - tableta - 50mg - vildagliptin
glypvilo 50mg tableta
krka, d.d., novo mesto, novo mesto array - 17128 vildagliptin - tableta - 50mg - vildagliptin